Pharma serving to regulated market are under stress due product price erosion. Market is comfortably giving higher multiples to step down segment in value chain i.e. raw material suppliers.
eg. Alkyl & Balaji Amine. Very few Pharma are growing well. But again, they can’t grow in isolation as the question is what makes them so special other than promoters? Stagnancy is imminent after certain size.
Hence investing in Raw material supplier (KSM) companies’ de-risk your portfolio. They don’t deal directly with FDA. End users (Pharma players) can’t afford to lose them due to regulatory issues and delays due to vendor switch.
KSM producers has multiple buyers & applications of their products hence don’t get affected if any one pharma finds price erosion. KSM business is mostly bulk scale, hence there is less risk to them from their peers, its tough for new players to reduce the cost further.
Though over the longer run prices goes down by extensive research & new processes.
Jubilant Ingravia has posted superb Q1 numbers which fetched my attention. Stock is trading below one year forward 15x PE multiples & 2x of sales.
Its super cheap for specialty chemical company with minor debt
Key points:
Super diversified product & client portfolio
Leadership position for many products in India and in the World
Last year company reduced debt by 600 Cr while lined up 900 Cr Capex for next 3 years
Company is vertically integrated, makes raw materials needed in-house. This makes them competitive. This means new players must establish similar manufacturing set up to sustain against Jubilant.
Example of Vertical integration of Ethanol value chain:
1.Molasses to Ethanol to Acetaldehyde to Pyridine derivatives to Nutritional products
2.Ethanol to acetic anhydride
3.Ethanol to ethyl acetate 4. Ethanol to acetic acid to ketene to Diketene
We need to compare Jubilant Ingrevia with companies like Alkyl amine, Laxmi Organics and Deepak nitrite to see the larger picture. Jubilant is working in Specialty chemicals, Pharma raw materials & Nutritional products.
Alkyl amine is serving Pharma while Deepak is in Specialty chemicals, all three have narrow range of products with diverse applications. Jubilant have diverse products with diverse applications. Laxmi organics has two products overlap with Jubilant i.e. Ethyl acetate and Diketene
I see striking difference in valuations between Jubilant and Alkyl amine. For the former I have extrapolated numbers like Q1 while laters I think are already at their peak of margins.
A company was a biggest wealth creator between year 2013-17, stock price moved 60x. Went into downtrend/consolidation for 4 years, now trying to move up.
Summarizing some reasons how this break out is supported by fundamentals.
Thread on #PDSMultinational A unique platform business model in the Textile sector.
The company design, souces & finace all kinds of textiles from 540 unorganized Asian manufacturers and supply to branded players in EU-USA. That's the platform business
The company started its own manufacturing in Bangladesh, India, and Sri Lanka. Doubling their Bangladesh capacity this year. #Dixon of textile in making.
Company finance & help debottleneck their sourcing partner, thus increase efficiency and reduce cost & time
Company operates three segments: Design-Sourcing, Manufacturing & Financing
OPM has improved from 1% to 5% in the last 5 years, which suggests the company is now well established
Recently bought #GlobusSpirits. I see good value in this counter, can give multifold returns in 2-3 yrs.
Broad summary:
1. The company has paid off 110 Cr debt in 4 years 2. Debt reduced from 252 Cr to 142 Cr 3. Doubling the capacity from 140 to 280 KLPD in WB
4. Paying debt & increasing capacity- very good sign 5. Currently running at 100% Capacity 6. Margins have improved in last 4 yrs (8% to 20%) 7. Cash has gone up to 58 Cr 8. Present across the value chain 9. Supplier of hand spirit to FMCG player
10. Got pan India access due to merger with Unibev 11. Huge scope to grow in franchise bottling 12. Globus today stands where #RadicoKhaitan was 4 years back (7x rise in market cap).
Ammonia is set to become World’s another renewable fuel. Sounds interesting? Thread.
Renewable fuels & energy storage solutions are the buzzing trends of the world. Increase in Solar & Wind energy harvesting efficiency have changed all the energy dynamics.
This is disrupting many traditional businesses and impacting human life positively. Technology is accelerating & facing the change is life.
An ammonia molecule is composed of one nitrogen atom and three hydrogen atoms & mostly was used in making urea fertilizer.
With the emerging new application of ammonia as a green fuel, there is a possibility of World facing ammonia crunch and hence can give pricing power to the manufacturers. 180 Million tons of ammonia is made annually, 40% of plants are old. China is the largest producer.
Great news from #Lupin for Phase 3 data on #Solosec for Trichomoniasis. Its supplemental New Drug Application (sNDA). Solosec is currently approved by the FDA to treat bacterial vaginosis (BV) in adult women, so no safety concerns. FDA would look for good efficacy data (1)
Firstly, no new antibiotics are discovered. Humans are under a continuous threat against microbes. Solesec is developed by Symbiomix Therapeutics, Lupin bought it in 2017 for $150M
In the trial, 92% of patients achieved the primary endpoint versus 1.5% in the placebo group (2)
The cure rate was 95%(56/59) for Solosec versus 1.7% (1/60) for placebo. Well-tolerated, no serious adverse events were observed in the trial.
If approved, can get 10-year exclusivity. This is big. Most of the topline goes to the bottom line in patented drugs (3)
Few API players showed a sudden jump in profit margins in the gone quarter. I am trying to connect the dots by comparing COVID affected the first half of 2020 with 2018 when China was cracking down pollution from end of 2017. This has led to similar supply chain disruption
(1)
during 2018 in polluting chemical industries. The companies like Sadhana nitrochem, HEG/GI, Mangalam/Kanchi were the few to name Indian players who got benefited. See the share price of these companies after the end of 2017. The situation changed and afterward supply chain
(2)
became normal & stock prices have gone down.
Coming to 2020, the Wuhan region in China which is a chemical production zone was affected due to COVID from mid-January. 70% Indian API & raw material comes from China, and switching on-off is not that quick in the
(3)